Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Retrospective Study to Evaluate Compliance to Therapy and Drug Survival of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis in Routine Daily Clinical Practice

Next Previous
X
Search
Trial Profile

Multicenter Retrospective Study to Evaluate Compliance to Therapy and Drug Survival of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis in Routine Daily Clinical Practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2013

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms REMISSION II
  • Sponsors Roche

    • Most Recent Events

    • 23 May 2013 Planned end date changed from 1 Oct 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Aug 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top